Novo Nordisk A/S (NYSE:NVO) Reaches New 52-Week Low - Should You Sell?

Novo Nordisk A/S (NYSE:NVO - Get Free Report) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $45.57 and last traded at $45.96, with a volume of 9665103 shares changing hands. The stock had previously closed at $47.22.Wall Street Analysts Forecast GrowthNovo Nordisk Stock Sinks—But Is a Bottom Finally In?A number of brokerages recently weighed in on NVO. Hsbc Global Res lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 31st. BNP Paribas started coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Wall Street Zen lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of "Hold" and an average target price of $93.67.Novo Nordisk A/S Stock Down 3.8%Will Hims & Hers Fall Along With Novo Nordisk?The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The business has a 50 day simple moving average of $68.43 and a 200-day simple moving average of $72.20. The firm has a market capitalization of $202.90 billion, a price-to-earnings ratio of 13.44, a P/E/G ratio of 1.48 and a beta of 0.63.Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.08. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.Institutional Trading of Novo Nordisk A/S3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingInstitutional investors have recently made changes to their positions in the company. Strategic Investment Solutions Inc. IL increased its stake in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after acquiring an additional 300 shares during the last quarter. Copeland Capital Management LLC grew its holdings in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter worth about $27,000. Park Square Financial Group LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at about $29,000. Finally, Stone House Investment Management LLC purchased a new stake in Novo Nordisk A/S in the 1st quarter valued at about $30,000. Hedge funds and other institutional investors own 11.54% of the company's stock.About Novo Nordisk A/S(Get Free Report)Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.